CoChat

Outcomes of Using High- or Low-Dose Atorvastatin in Patients 65 Years of Age or Older with Stable Coronary Heart Disease

Wenger, Nanette K., Lewis, Sandra J., Herrington, David M., Bittner, Vera, Welty, Francine K., for the Treating to New Targets Study Steering Committee and Investigators · 2007 · Annals of Internal Medicine

The DOI matches its Crossref record; 19 of the 20 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Increased life expectancy is associated with an increase in the burden of chronic cardiovascular disease. OBJECTIVE: To assess the efficacy and safety of high-dose atorvastatin in patients 65 years of age or older. DESIGN: A prespecified secondary analysis of the Treating to New Targets study, a randomized, double-blind clinical trial. SETTING: 256 sites in 14 countries participating in the Treating to New Targets study. PARTICIPANTS: 10,001 patients (3809 patients > or =65 years of age) with coronary heart disease (CHD) and low-density lipoprotein cholesterol levels less than 3.4 mmol/L (<130 mg/dL). INTERVENTION: Patients were randomly assigned to receive atorvastatin, 10 or 80 mg/d. MEASUREMENTS: The primary end point was the occurrence of a first major cardiovascular event (death from CHD, nonfatal non-procedure-related myocardial infarction, resuscitated cardiac arrest, or fatal or nonfatal stroke). RESULTS: In patients 65 years of age or older, absolute risk was reduced by 2.3% and relative risk by 19% for major cardiovascular events in favor of the high-dose atorvastatin group (hazard ratio, 0.81 [95% CI, 0.67 to 0.98]; P = 0.032). Among the components of the composite outcome, the mortality rates from CHD, nonfatal non-procedure-related myocardial infarction, and fatal or nonfatal stroke (ischemic, embolic, hemorrhagic, or unknown origin) were all lower in older patients who received high-dose atorvastatin, although the difference was not statistically significant for each individual component. The improved clinical outcome in patients 65 years of age or older was not associated with persistent elevations in creatine kinase levels. LIMITATION: Because the study was a secondary analysis, the findings should be interpreted within the context of the main study results. CONCLUSIONS: The analysis suggests that additional clinical benefit can be achieved by treating older patients with CHD more aggressively to reduce low-density lipoprotein cholesterol levels to less than 2.6 mmol/L (<100 mg/dL). The findings support the use of intensive low-density lipoprotein cholesterol-lowering therapy in high-risk older persons with established cardiovascular disease. Click here for related information on atorvastatin.

Overview

Integrity signals

Registry

Crossref · 10.7326/0003-4819-147-1-200707030-00002

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 19 references

Cited by

See all 140

Metadata

Authors
Wenger, N. K., Lewis, S. J., Herrington, D. M., Bittner, V., Welty, F. K., & for the Treating to New Targets Study Steering Committee and Investigators
Affiliations
Beth Israel Deaconess Medical Center (US)
Venue
Annals of Internal Medicine
Published
2007-07-03
Volume
147
Issue
1
Pages
1-9
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2155270329
Cited by
139
References
20
Citations by year
2026: 2 · 2022: 1 · 2021: 4 · 2020: 4 · 2019: 9 · 2018: 4 · 2017: 1 · 2016: 8 · 2015: 8 · 2014: 10 · 2013: 9 · 2012: 8
FWCI
19.91
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations
  • Annals of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • UCLA - Biblioteca de Ciencias de la Salud (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Keywords
atorvastatin, high-intensity statin therapy, stable coronary artery disease, older adults, major adverse cardiovascular events, LDL cholesterol targets, creatine kinase elevation, statin safety, secondary prevention, myocardial infarction, stroke, cardiovascular mortality, hypercholesterolemia, intensive lipid lowering
MeSH terms
Atorvastatin, Age Factors, Aged, Aged, 80 and over, Anticholesteremic Agents, Cardiovascular Diseases, Coronary Disease, Female, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Pyrroles, Triglycerides, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Outcomes of Using High- or Low-Dose Atorvastatin in Patients 65 Years of Age or Older with Stable Coronary Heart Disease. https://app.cochat.ai/papers/10.7326/0003-4819-147-1-200707030-00002
The paper
Wenger, N. K., Lewis, S. J., Herrington, D. M., Bittner, V., Welty, F. K., & for the Treating to New Targets Study Steering Committee and Investigators. (2007). Outcomes of Using High- or Low-Dose Atorvastatin in Patients 65 Years of Age or Older with Stable Coronary Heart Disease. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-147-1-200707030-00002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.